Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension

Journal of Hepatology

Volumn 52, Issue 4, 2010, Pages 529-539

  Mejias, Marc ^a   Garcia Pras, Ester ^a   Gallego, Javier ^a   Mendez, Raul ^b   Bosch, Jaime ^a   Fernandez, Mercedes ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

mTOR signaling; Portal hypertension; Splenomegaly

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; MAMMALIAN TARGET OF RAPAMYCIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RAPAMYCIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FIBROGENESIS; FIBROSIS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SPLEEN; SPLEEN SIZE; SPLENOMEGALY; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL DIVISION; FIBROSIS; HEMATOCRIT; HYPERTENSION, PORTAL; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOCYTES; LYMPHOID TISSUE; MALE; NEOVASCULARIZATION, PATHOLOGIC; ORGAN SIZE; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SIROLIMUS; SPLEEN; SPLENOMEGALY;

EID: 77949875704     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.01.004     Document Type: Article

References (36)

1. McCormick P.A., and Murphy K.M. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Baillieres Best Pract Res Clin Gastroenterol 14 (2000) 1009-1031
2. Afdhal N., McHutchison J., Brown R., Jacobson I., Manns M., Poordad F., et al. Thrombocytopenia associated with chronic liver disease. J Hepatol 48 (2008) 1000-1007
3. Berzigotti A., Zappoli P., Magalotti D., Tiani C., Rossi V., and Zoli M. Spleen enlargement on follow-up evaluation: a noninvasive predictor of complications of portal hypertension in cirrhosis. Clin Gastroenterol Hepatol 6 (2008) 1129-1134
4. Moschowitz E. The pathogenesis of splenomegaly in hypertension of the portal circulation: congestive splenomegaly. Medicine 27 (1988) 187-210
5. Bolognesi M., Merkel C., Sacerdoti D., Nava V., and Gatta A. Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis 34 (2002) 144-150
6. Inoki K., and Guan K.L. Complexity of the mTOR signaling network. Trends Cell Biol 16 (2006) 206-212
7. Schmelzle T., and Hall M.N. TOR, a central controller of cell growth. Cell 103 (2000) 253-262
8. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 18 (2004) 1926-1945
9. Viñals F., Chambard J.C., and Pouyssegur J. P70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. J Biol Chem 274 (1999) 26776-26782
10. Mayerhofer M., Valent P., Sperr W.R., Griffin J.D., and Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target or rapamycin. Blood 100 (2002) 3767-3775
11. Humar R., Kiefer F.N., Berns H., Resink T.J., and Battegay E.J. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16 (2002) 771-780
12. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 (2002) 128-135
13. Biecker E., De Gottardi A., Neef M., Unternährer M., Schneider V., Ledermann M., et al. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J Pharmacol Exp Ther 313 (2005) 952-961
14. Neef M., Ledermann M., Saegesser H., Schneider V., and Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 45 (2006) 786-796
15. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4 (2004) 335-348
16. Tsang C.K., Qi H., Liu L.F., and Zheng X.F. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 12 (2007) 112-124
17. Choi J., Chen J., Schreiber S.L., and Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273 (1996) 239-242
18. Edinger A.L., Linardic C.M., Chiang G.G., Thompson C.B., and Abraham R.T. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res 63 (2003) 8451-8460
19. Fernandez M., Mejias M., Garcia-Pras E., Mendez R., Garcia-Pagan J.C., and Bosch J. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology 46 (2007) 1208-1217
20. Yatscoff R.W., Wang P., Chan K., Hicks D., and Zimmerman J. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 17 (1995) 666-671
21. Mejias M., Garcia-Pras E., Tiani C., Miquel R., Bosch J., and Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49 (2009) 1245-1256
22. Fernandez M., Vizzutti F., Garcia-Pagan J.C., Rodes J., and Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 126 (2004) 886-894
23. Fernandez M., Mejias M., Angermayr B., Garcia-Pagan J.C., Rodes J., and Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 43 (2005) 98-103
24. Fernandez M., Semela D., Bruix J., Colle I., Pinzani M., and Bosch J. Angiogenesis in liver disease. J Hepatol 50 (2009) 604-620
25. Drenckhahn D., and Wagner J. Stress fibres in the splenic sinus endothelium in situ: molecular structure, relationship to the extracellular matrix, and contractility. J Cell Biol 102 (1986) 1738-1747
26. Andrae J., Gallini R., and Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22 (2008) 1276-1312
27. Maesawa C., Sakuma T., Sato T., Masuda T., Muro-oka G., and Satodate R. Structural characteristics of splenic sinuses in idiopathic portal hypertension. Pathol Int 45 (1995) 642-648
28. Gerlach C., Golding M., Larue L., Alison M., and Gerdes J. Ki-67 immunoexpression is a robust marker of proliferative cells in the rat. Lab Invest 77 (1997) 697-698
29. Mebius R.E., and Kraal G. Structure and function of the spleen. Nat Rev Immunol 5 (2005) 606-616
30. Abbas A.K. Die and let live: eliminating dangerous lymphocytes. Cell 84 (1996) 655-657
31. Downward J. How BAD phosphorylation is good for survival. Nat Cell Biol 1 (1999) E33-E35
32. Marx S.O., Jayaraman T., Go L.O., and Marks A.R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76 (1995) 412-417
33. Abraham N.G., and Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 60 (2008) 79-127
34. Lok S., Kaushansky K., Holly R.D., Kuijper J.L., Lofton-Day C.E., Oort P.J., et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369 (1994) 565-568
35. McHutchison J.G., Dusheiko G., Shiffman M.L., Rodriguez-Torres M., Sigal S., Bourliere M., et al. Elthrombopag for thrombocytopenia in patients with cirrhosis associated hepatitis C. N Engl J Med 357 (2007) 2227-2236
36. Folkman J., and D́Amore P.A. Blood vessel formation: what is its molecular basis?. Cell 87 (1996) 1153-1155